Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome

Micah K. Harris1 | Richard T. Graham2 | Andréa M. Cappellano3 | Ashley S. Margol4 | George Michail4 | John R. Crawford5 | Myrsini Ioaikim-Ioannidou7 | Joseph R. Stanek6 | Kevin X. Liu7 | Shannon M. MacDonald7 | Mohamed S. Abdelbaki8

1The Ohio State University College of Medicine, Columbus, Ohio, USA
2Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA
3Pediatric Oncology, IOP-GRAACC/Federal University of São Paulo, São Paulo, Brazil
4Division of Hematology, Oncology and Blood & Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, California, USA
5Department of Neurology, Children’s Health Orange County, Orange, California, USA
6The Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children’s Hospital and The Ohio State University, Columbus, Ohio, USA
7Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
8The Division of Hematology and Oncology, St. Louis Children’s Hospital, Washington University, School of Medicine in St. Louis, Washington University, St. Louis, Missouri, USA

Correspondence
Mohamed S. Abdelbaki, 660 South Euclid Ave, Campus Box 8116, St. Louis, MO 63110, USA. Email: mohameda@wustl.edu

Abstract

Purpose: Primary germ cell tumors (GCTs) are the most common central nervous system (CNS) neoplasm in patients with Down syndrome (DS). However, a standard of care has not been established due to paucity of data.

Methods: A retrospective multi-institutional analysis was conducted, in addition to a comprehensive review of the literature.

Results: Ten patients from six institutions (five USA, one Brazil) were identified, in addition to 31 patients in the literature from 1975 to 2021. Of the 41 total patients (mean age 9.9 years; 61% male), 16 (39%) had non-germinomatous germ cell tumors (NGGCTs), 16 (39%) had pure germinomas, and eight (19.5%) had teratomas. Basal ganglia was the most common tumor location (n = 13; 31.7%), followed by posterior fossa (n = 7; 17%). Nine patients (22%) experienced disease relapse or progression, of which four died from tumor progression (one germinoma, three teratomas). Basal ganglia was the most common tumor location (n = 13; 31.7%), followed by posterior fossa (n = 7; 17%). Nine patients (22%) experienced disease relapse or progression, of which four died from tumor progression (one germinoma, three teratomas). Sixteen patients (39%) experienced treatment-related complications, of which eight (50%) died (five germinomas, three NGGCTs). Of the germinoma patients, two died from chemotherapy-related sepsis, one from postsurgery cardiopulmonary failure, one from pneumonia, and one from moyamoya following radiation therapy (RT). Of the NGGCT patients, one died from chemotherapy-related sepsis, one from postsurgical infection, and one from pneumonia following surgery/chemotherapy/RT. Three-year overall survival was 66% for all histological types: 62% germinomas, 79% for NGGCTs, and 53% for teratomas.

Conclusion: Patients with DS treated for CNS GCTs are at an increased risk of treatment-related adverse events. A different therapeutic approach may need to be considered to mitigate treatment-related complications and long-term neurocognitive sequelae.

KEYWORDS
central nervous system, Down syndrome, germ cell tumor, intracranial

Abbreviations: AFP, alfa fetoprotein; AML, acute myeloid leukemia; bHCG, beta human chorionic gonadotropin; CI, confidence interval; CNS, central nervous system; CPA, cerebellopontine angle; CR, complete response; CSF, cerebrospinal fluid; DS, Down syndrome; GCT, germ cell tumor; GTR, gross total resection; NED, no evidence of disease; NGGCT, non-germinomatous germ cell tumor; OS, overall survival; RT, radiotherapy; STGC, germinoma with syncytiotrophoblastic giant cells; WBRT, whole-brain radiotherapy; WVI, whole-ventricle irradiation; YST, yolk sac tumor.
1 | INTRODUCTION

Central nervous system (CNS) germ cell tumors (GCTs) make up <4% of primary pediatric brain tumors, with incidence rates increasing among males, individuals <20 years old, and Eastern Asian populations.1 CNS GCTs can be broadly classified as germinomas, non-germinomatous GCTs (NGGCTs), or teratomas.1 Based on histological components, NGGCTs can be classified into embryonal carcinomas, yolk sac tumors (YSTs), choriocarcinomas, GCTs with mixed components (mixed GCTs), or germinoma with syncytiotrophoblastic giant cells (STGCs).1 Teratomas may be divided into mature teratomas, immature teratomas or teratomas with malignant transformation.1

Down syndrome (DS) has classically been associated with higher rates of blood cancers such as acute myeloid leukemia (AML).2 The incidence of solid tumors in patients with DS is rare, yet GCTs have been found to make up a disproportionate number of intracranial tumors as compared to the general population.3 Though associations between CNS GCTs and DS have been reported, the small number of cases is limiting: the most recent literature review reported just 21 patients with CNS GCTs and DS, with almost all studies arising from Japan or China.4 This paucity of cases, particularly of those from Northern America, has limited our understanding of this patient population.

The standard of care for CNS GCTs includes a combination of surgery, platinum-based chemotherapy, and radiotherapy (RT), with specific treatments varying by tumor subtype and individual institution.1 In patients with DS, treatment is complicated by their increased risk of developing acute and long-term treatment-related adverse effects. Patients with DS are at an increased risk of RT-related cognitive impairments and cerebrovascular disease given their baseline cognitive impairments, decreased cerebral volume, and predisposition to degenerative neurologic disease.5,6 Moreover, it is well documented that patients with DS are highly susceptible to toxicities related to standard chemotherapy drugs used in AML; these include treatment-related infection, mucositis from methotrexate therapy, anthracycline-induced cardiomyopathy, and even fatal neurotoxicity.5,7

Due to the complexity of care and rarity of cases, a standard treatment approach that promotes both optimal survival and minimization of treatment-related adverse effects in patients with CNS GCTs and DS has not been established. Here, we describe a multinational and multi-institutional retrospective analysis of patients diagnosed with DS and CNS GCTs, in addition to a review of the literature.

2 | METHODS

2.1 | Study design and participants

A comprehensive literature search was performed using PubMed/ MEDLINE and Google Scholar. Major academic institutions across the United States, Brazil, and Australia were systematically contacted and provided with a de-identified data collection form. Each participating center received approval from their local institutional review board.

2.2 | Data

The following data were collected: sex, age at diagnosis, presenting symptoms and duration, ethnicity, primary tumor site, histology, serum/cerebrospinal fluid (CSF) tumor markers, including beta human chorionic gonadotropin (bHCG) and alfa fetoprotein (AFP), extent of surgical resection, RT regimen, chemotherapy regimen, treatment sequence, response to treatment, time to progression, relapse timing, relapse treatment, duration of survival, cause of death, and treatment-related adverse events. Treatment-related toxicities were classified according to the Common Terminology Criteria for Adverse Events Version 5.0. Elevated bHCG and AFP cutoffs were determined by each institution.

2.3 | Statistical analysis

All data were summarized with standard descriptive statistics. Overall survival (OS) and corresponding 95% confidence intervals (CI) were calculated and presented using the Kaplan–Meier method. Comparison of survival curves was performed using log-rank (Mantel–Cox) tests. p-Values <.05 were considered statistically significant. Statistical analyses were calculated and graphics designed using Prism 9 software (GraphPad, La Jolla, CA, USA).

3 | RESULTS

3.1 | Patient characteristics

Demographics are summarized in Table 1 and clinical information in Table 2. A comprehensive review of the literature revealed 31 patients in 26 manuscripts from the years 1975 to 2021.4,8–32 Most studies originated from East Asia (22/26). A review of tertiary institutions identified nine patients from five academic institutions in the United States (Nationwide Children’s Hospital, Columbus, OH; St. Jude Children’s Research Hospital, Memphis, TN; Rady Children’s Hospital, San Diego, CA; Children’s Hospital Los Angeles, Los Angeles, CA; Massachusetts General Hospital, Boston, MA) and one patient from Brazil (Federal University of São Paulo, Vila Clementino, São Paulo, BR). Of the 41 total patients, mean age was 9.9 years (range: newborn to 35 years). The majority (90%) of patients were ≤18 years of age. Age was unreported in one patient. A male predominance was noted (61%).

Sixteen patients had germinomas (39%), 16 had NGGCTs (39%) and eight had teratomas (20%); tumor histology was not reported for one patient. Of the NGGCTs, seven were YSTs (17%), two were embryonal carcinomas (4.9%), one was STGC (2.4%), three were mixed GCTs (7.3%), and three were unspecified (7.3%). Of the teratomas, five were immature (12%), one was mature (2.4%), and two were unspecified (4.9%). Thirteen tumors were localized to the basal ganglia (32%), seven the posterior fossa (17%), three the pineal region (7.3%), and
TABLE 1  Demographics

| N | %   |
|---|-----|
| Total | 41 | 100 |
| Mean age, years (range) | 9.9 (newborn to 35) |
| Sex |
| Male | 25 | 61 |
| Female | 16 | 39 |
| Histology\(^a\) |
| Germinoma | 16 | 39 |
| NGGCT | 16 | 39 |
| Teratoma | 8 | 20 |
| Mature teratoma | 1 | 2.4 |
| Immature teratoma | 5 | 12 |
| Unspecified teratoma | 2 | 4.9 |
| Primary site |
| Basal ganglia | 13 | 31.7 |
| Posterior fossa | 7 | 17 |
| Pineal | 3 | 7.3 |
| Sellar/suprasellar | 8 | 19.5 |
| Other | 4 | 9.8 |
| Multiple intracranial sites | 6 | 14.6 |
| Spinal metastasis | 3 | 7.3 |
| Elevated markers if tested |
| Serum \(\beta\)HCG | 11 | 39 |
| Serum AFP | 14 | 58 |
| CSF \(\beta\)HCG | 4 | 33 |
| CSF AFP | 6 | 22.9 |
| Response to initial therapy |
| Complete response | 26 | 63 |
| Partial response | 10 | 24 |
| Progressive disease | 5 | 12 |
| Tumor relapse | 9 | 21 |
| Outcome |
| Alive at last follow-up | 29 | 70.7 |
| Deceased from tumor | 4 | 9.8 |
| Deceased from treatment | 8 | 19.5 |

Abbreviations: AFP, alpha fetoprotein; \(\beta\)HCG, beta human chorionic gonadotropin; CSF, cerebrospinal fluid; NED, no evidence of disease; NGGCT, non-germinomatous germ cell tumor.

\(^a\)Histology for one patient was not reported.

Eight the sellar or suprasellar region (20%). Other tumors were localized to the third ventricle, fourth ventricle, and cerebellopontine angle (CPA). Six patients (15%) presented with multiple intracranial lesions: basal ganglia/thalamus, basal ganglia/frontal lobe, pineal/suprasellar, pineal/CPA, and ventral midbrain/CPA/pineal. Of these six patients, two had additional metastatic disease to the spine. One tumor was localized to the sellar region with spinal metastases.

3.2 Clinical presentation and tumor markers

Presenting symptoms were reported for 33 patients (81%). Duration of symptoms was available for 18 patients (44%) and ranged from 1 week to 2.5 years (mean 6.9 months). Six of these patients (20%) had symptoms for greater than 6 months. Of the 33 patients whose presenting symptoms were reported, hemiparesis (24%) was the most common symptom, followed by visual disturbance (20%), nausea/vomiting (17%), lethargy (15%), headache (15%), polyuria (12%), ataxia (9.8%), motor impairment (9.8%), polydipsia (9.8%), head enlargement (7.3%), seizures (2.4%), amenorrhea (2.4%), and facial nerve palsy (2.4%); one tumor was identified on prenatal ultrasound.

Serum AFP and \(\beta\)HCG were tested in 25 and 28 patients, respectively. Of these patients, 14 (58%) had elevated serum AFP and 11 (39%) had elevated serum \(\beta\)HCG. CSF AFP and \(\beta\)HCG were tested in 14 and 12 patients, respectively. Of these patients, six (43%) had elevated CSF AFP and four (33%) had elevated CSF \(\beta\)HCG. In those with both serum and CSF testing, serum AFP matched CSF AFP in 11 of 12 patients (92%), while serum \(\beta\)HCG matched CSF \(\beta\)HCG in 11 of 12 patients (92%), while serum \(\beta\)HCG matched CSF \(\beta\)HCG in nine of 10 patients (90%). Overall, 17 of 31 patients (55%) had elevated AFP, while 12 of 35 patients (34%) had elevated \(\beta\)HCG at initial diagnosis.

3.3 Treatment and response

Treatment approaches are summarized in Table 3. Of the patients with germinomas \((n = 16)\), nine (56%) underwent surgical biopsy and seven (47%) underwent subtotal resection (STR). Ten patients (63%) received chemotherapy. All chemotherapies were platinum based. Only one patient received chemotherapy alone. Of the patients who underwent combined chemotherapy/RT, all patients received chemotherapy prior to RT. Fourteen patients (88%) received RT; two patients (13%) received craniospinal irradiation (CSI) (mean 2370 cGy), three (19%) received whole-brain radiotherapy (WBRT) (mean 29.3 Gy), four (25%) received whole-ventricle irradiation (WVI) (mean 27 Gy), four (25%) received focal RT (mean 30 Gy), and one (6.3%) received an unspecified regimen. Four patients (25%) received primary site boost (mean total dose 43.3 Gy; three WVI, one CSI). Complete response (CR) was achieved in nine patients (56%) following therapy.

Of the patients with NGGCTs \((n = 16)\), five (31%) underwent surgical biopsy (three YSTs, one mixed GCT, one embryonal carcinoma), three (19%) underwent gross total resection (GTR) (two YSTs, one STGC), and four (25%) underwent STR (two YSTs, one embryonal carcinomas, one mixed GCT). Fifteen patients (93%) received chemotherapy; 10 (63%) received combined chemotherapy/RT (three YSTs, three mixed GCTs, one STGC, three unspecified), and four (25%) received chemotherapy only (two YSTs, two embryonal carcinomas). All chemotherapies were platinum based. One patient received no adjuvant therapy (one YST). Ten patients (63%) received RT; four (25%) received CSI (mean 22.5 Gy), two (13%) received WBRT (mean 25.5 Gy), one (6.3%) received WVI (dose unreported), two (13%) received focal RT (mean 45.6 Gy), and one (6.3%) received an unspecified regimen. Three
TABLE 2  Selected clinical information for patients found in the literature (cases 1–31) and on multi-institutional review (cases 32–41)

| Case | Age | Path. | 1st site(s) | Surgery | RT field: dose Gy (boost) | Chemotherapy | Response | Outcome | OS (months) | COD      |
|------|-----|-------|-------------|---------|--------------------------|--------------|----------|---------|-------------|----------|
| 1    | 13 years | NG | BG | Bx | WBI: 30 | Ifos, Carbo, Etop | CR | Alive | 21 | NA |
| 2    | 2 years | T  | CB | Bx | No | No | PD | Dead | 2 | Tumor |
| 3    | 7 years | T  | V  | Bx | Yes: NR | No | PD | Dead | 2 | Tumor |
| 4    | 4 months | T  | BG | Bx | No | No | PD | Dead | 7 | Tumor |
| 5    | 9 years | G  | BG | STR | Yes: NR | No | CR | Alive | 36 | NA |
| 6    | 12 years | NG | BG | STR | Yes: NR | Cisplatin, Etop | PR | Alive | NR | NA |
| 7    | 6 years | NG | CB | STR | No | Cisplatin, bleomycin, VBL, Cyclo | CR | Dead | NR | Sepsis |
| 8    | 12 years | NG | BG | GTR | WBI: 21 | Cisplatin, Etop | PR | Dead | 21 | Pneumonia |
| 9    | 11 years | NR | BG | None | Yes: NR | No | PD | Dead | NR | NR |
| 10   | 10 years | G  | BG | STR | Focal: 30 | Cisplatin, Etop | CR | Alive | NR | NA |
| 11   | 10 years | G  | BG/T | STR | No | No | PR | Dead | 1 | CP failure |
| 12   | 20 years | G  | P  | STR | Focal: 40 | Paraplatin, Etop | PR | Alive | NR | NA |
| 13   | 9 years | G  | BG | STR | No | Cisplatin, Etop, bleomycin | CR | Dead | 11 | Sepsis |
| 14   | 3 years | NG | CB | GTR | No | Cisplatin, Etop, bleomycin | CR | Alive | 36 | NA |
| 15   | 22 years | NG | S  | Bx | No | No | PR | Dead | 1.5 | Infection |
| 16   | 35 years | G  | P/CB; Mets | Bx | Local: 42 | Carbo, Etop | CR | Dead | 35 | Tumor |
| 17   | 17 years | NG | BG | Bx | Yes: NR | Ifos, cisplatin, Etop | PR | Alive | NR | NA |
| 18   | 2 months | T  | CB | GTR | No | Cisplatin, Etop | CR | Alive | 46 | NA |
| 19   | Newborn | T  | P  | GTR | No | No | CR | Alive | 3 | NA |
| 20   | 12 years | G  | BG | STR | WBI: 40; spine: 26 | No | CR | Alive | 60 | NA |
| 21   | 14 years | G  | BG | Bx | WBI: 24 | Ifos, cisplatin, Etop | CR | Alive | 16 | NA |
| 22   | 1.5 years | NG | PF | GTR | No | Cisplatin, Etop, bleomycin | CR | Alive | 23 | NA |
| 23   | 17 years | NG | S  | STR | No | Carbo, Etop, cisplatin, benduximab-vendotin | CR | Alive | 24 | NA |
| 24   | 18 years | G  | CB/P/MB; Mets | Bx | CSI: 23.4 | Carbo, Etop | PR | Alive | 21 | NA |
| 25   | 15 years | G  | BG | Bx | WBI: 30 | Ifos, cisplatin, Etop | PR | Dead | 11 | Sepsis |
| 26   | 1 year | NG | V  | STR | Local: 41.4 | Ifos, cisplatin, Etop | CR | Alive | 154 | NA |
| 27   | 8 years | NR | BG | Bx | WBI: 24; local: 24 | Carboplatin, Etop, Ifos | PR | Alive | 60 | NA |
| 28   | 6 months | NG | P/S | None | CSI: 18 | Carboplatin, Etop, Ifos, thiopeta | CR | Alive | 96 | NA |
| 29   | 7 months | G  | S  | STR | WBI: NR | No | CR | Dead | 48 | Moyamoya |
| 30   | 4 months | T  | PF | GTR | No | Etop, carboplatin, bleomycin | CR | Alive | 216 | NA |
| 31   | NR | G  | S  | None | WVI: NR | Etop, carboplatin, bleomycin | CR | Alive | 72 | NA |
| 32   | 15.8 years | G  | S; Mets | Bx | CSI: 24 (40) | No | PR | Alive | 6 | NA |
| 33   | 8.8 years | NG | P  | Bx | CSI: 36 | Carboplatin, Etop, Cyclo | CR | Alive | NR | NA |

(Continues)
Table 2 (Continued)

| Case | Age     | Path. | 1<sup>st</sup> site(s) | Surgery | RT field: dose Gy (boost) | Chemotherapy                     | Response | Outcome | OS (months) | COD |
|------|---------|-------|-------------------------|---------|---------------------------|----------------------------------|----------|---------|-------------|-----|
| 34   | 2 months| T     | PF                      | GTR     | No                        | No                               | CR       | Alive   | NR           | NA  |
| 35   | 17.2 years| NG    | S                       | STR     | No                        | Carboplatin, Etop, thiotepa      | CR       | Alive   | NR           | NA  |
| 36   | 8 years  | G     | S                       | Bx      | WVI: 24 (36)              | Carboplatin, Etop, thiotepa      | CR       | Alive   | 70           | NA  |
| 37   | 12.7 years| NG    | S                       | None    | WVI: NR                   | Carboplatin, Etop, Ifos, Cyclo, thiotepa | CR       | Alive   | 14.5         | NA  |
| 38   | 6.7 years| NG    | S/P/V                   | None    | CSI: 18 (27)              | Carbo, Etop, Ifos, thiotepa      | CR       | Alive   | 18           | NA  |
| 39   | 4 months | T     | PF                      | GTR     | No                        | Carboplatin, Etop, bleomycin     | CR       | Alive   | 255          | NA  |
| 40   | 6.7 years| G     | S/P/V                   | None    | CSI: 18 (27)              | Carboplatin, Cyclo, Etop, VCR, thiotepa | CR       | Alive   | 115          | NA  |
| 41   | 34.7 years| G     | S                        | Bx      | Local: 36                 | No                               | PD       | Alive   | 10           | NA  |

Abbreviations: 1<sup>st</sup>, primary; BG, basal ganglia; Bx, biopsy; Carbo, carboplatin; CB, cerebellum; COD, cause of death; CP, cardiopulmonary; CR, complete response; CSI, craniospinal irradiation; Cyclo, cyclophosphamide; Etop, etoposide; GTR, gross total resection; Ifos, ifosfamide; mets, metastatic; NA, not applicable; NR, not reported; P, pineal; Path, pathology; PF, posterior fossa; PR, partial response; RT, radiotherapy; S, sellar/suprasellar; STR, subtotal resection; T, thalamus; Tx, treatment; V, ventricle; VCR, vincristine; WBI, whole-brain irradiation; WVI, whole-ventricular irradiation.

Table 3

| Treatment | Total | Germinoma | Germinoma | NGGCT | NGGCT | Teratoma | Teratoma |
|-----------|-------|-----------|-----------|-------|-------|----------|----------|
|           | N     | N         | N         | N     | N     | N        | N        |
| Radiation | 27    | 14        | 88        | 11    | 69    | 1        | 13       |
| Chemotherapy | 26    | 10        | 63        | 15    | 94    | 3        | 38       |
| Surgery   | 34    | 15        | 94        | 12    | 75    | 8        | 100      |

Treatment comparison

| Treatment | N | % | N | % | N | % | N | % |
|-----------|---|---|---|---|---|---|---|---|
| RT only<sup>a</sup> | 1 | 2.4 | 0 | 0 | 0 | 0 | 0 | 0 |
| RT + biopsy | 3 | 7.3 | 2 | 13 | 0 | 0 | 1 | 13 |
| RT + STR | 3 | 7.3 | 3 | 19 | 0 | 0 | 0 | 0 |
| RT + chemotherapy | 5 | 12 | 1 | 6.3 | 4 | 25 | 0 | 0 |
| RT + biopsy + chemo | 9 | 21 | 6 | 38 | 3 | 19 | 0 | 0 |
| RT + STR + chemo | 4 | 9.8 | 2 | 13 | 2 | 13 | 0 | 0 |
| RT + GTR + chemo | 2 | 4.9 | 0 | 0 | 2 | 12.5 | 0 | 0 |
| Chemo + biopsy | 1 | 2.4 | 0 | 0 | 1 | 6.3 | 0 | 0 |
| Chemo + STR | 3 | 7.3 | 1 | 6.3 | 2 | 13 | 0 | 0 |
| Chemo + GTR | 4 | 9.8 | 0 | 0 | 1 | 6.3 | 3 | 38 |
| Biopsy only | 3 | 7.3 | 0 | 0 | 1 | 6.3 | 2 | 25 |
| STR only | 1 | 2.4 | 1 | 6.3 | 0 | 0 | 0 | 0 |
| GTR only | 2 | 4.9 | 0 | 0 | 0 | 0 | 2 | 25 |

<sup>a</sup>Histology was unspecified for one patient who was treated with RT only.

Abbreviations: Chemo, chemotherapy; GTR, gross total resection; NGGCT, non-germinomatous germ cell tumor; RT, radiotherapy; STR, subtotal resection.
patients (19%) received primary site boost (mean total dose 27 Gy). CR was achieved in 12 patients (75%) following therapy.

Of the patients with teratomas (n = 8), three (38%) underwent surgical biopsy only (one immature teratoma, two unspecified teratomas) and five (63%) underwent GTR (four immature teratomas, one mature teratoma). Adjuvant therapy was chemotherapy only (three immature teratomas) or RT only (one unspecified teratoma). All chemotherapy regimens were platinum based. Five patients (62.5%) achieved CR following therapy.

### 3.4 Treatment-related adverse events

Treatment-related adverse events are summarized in Table 4. Sixteen patients (39%) experienced grade 3–5 treatment-related complications. grade 3–4 myelosuppression occurred in five patients. Nine patients experienced grade 3–5 infections, which included four episodes of sepsis, three episodes of pneumonia, one episode of mucositis, and one postsurgical infection of unknown origin. One patient experienced postsurgical cardiopulmonary failure and one experienced moyamoya following RT. Of the 16 patients, nine received combined chemotherapy/RT, four received chemotherapy only, one received RT only, and two underwent surgery without adjuvant therapy. Of the 16 patients who experienced adverse events, eight (50%) died of their complications.

### 3.5 Outcomes

Time to follow-up was available for 32 patients (mean 3.9 years; range: 1 month to 21.2 years). Overall, nine patients (21%) experienced disease relapse or progression; four patients experienced local relapse after CR (one germinoma, one teratoma, two NGGCTs), and five patients experienced disease progression despite therapy. Of the four patients who experienced local relapse, salvage regimens included platinum-based chemotherapy (n = 3), repeat surgery (n = 2), and RT (n = 1). Three patients who experienced disease relapse were successfully salvaged and had no evidence of disease (NED) at last follow-up, whereas one died from treatment-related pneumonia. Four patients who had progressive disease died, while one remained alive with residual tumor at last follow-up.

Overall, four patients (9.8%) died from tumor progression (three teratomas, one germinoma), while the remaining eight patients (19.5%) died from treatment-related adverse events. Of the germinoma patients, two died from chemotherapy-related sepsis, one from pneumonia, one from postsurgery cardiopulmonary failure, and one from moyamoya following RT only. Of the NGGCT patients, one died from chemotherapy-related sepsis, one from postsurgical infection, and one from pneumonia following surgery/chemotherapy/RT.

At last follow-up, 28 patients (68%) were alive with NED and one patient (2.4%) was alive with residual tumor. The 3-year OS for all histological types was 66% (95% CI: 45.7%–81.5%). Three-year OS was 62% for germinomas (95% CI: 30.5%–85.5%), 79% for NGGCTs (95% CI: 38%–94.3%), and 53% for teratomas (95% CI: 13.2%–82.5%) (Figure 1A). There was no significant difference in 3-year OS based on histology (p = .74). Three-year OS was 74.7% (95% CI: 47.4%–89.9%) for those who received RT, 76.7% (95% CI: 48.2%–90.8%) for chemotherapy, and 72.4% (95% CI: 44.7%–90.5%) for combined chemotherapy/RT (Figure 1B). There was no significant difference in 3-year OS based on treatment (p = .87).

### 4 Discussion

In 1998, Satge et al. reported that GCTs make up nearly a third of intracranial tumors in patients with DS, whereas they account for <4% in the general pediatric population. Though a mechanism for this interaction is unestablished, DS is known to predispose to the development of gonadal GCTs through various mechanisms. Few patients with DS and CNS GCTs have since been reported. This study includes the largest reported cohort of patients with DS and CNS GCTs and provides insight into the characteristics, management, and outcomes of this population.

Genetic and environmental differences influence the occurrence of CNS GCTs, as evidenced by differences in incidence by geographical location. GCTs account for <5% of all childhood CNS tumors in the United States, Germany, and Canada. In contrast, GCTs account for 2.1%–9.4% in Japan and the Far East. Race and ethnicity also play a role, as an analysis of the SEER database by Poynter et al. showed higher incidence rates of CNS GCTs in patients of Asian/Pacific Islander descent irrespective of gender, tumor location, and histology. Consistent with these findings, the majority of studies we identified in the literature (22/26) originated from Japan or China. Consistent with prior studies, CNS GCTs were also seen most frequently in male patients. Male sex has been strongly associated with pineal involvement, whereas suprasellar involvement has been associated with female sex. In our study, pineal localization showed a slight male predominance (5/9; 56%), whereas sellar/suprasellar involvement showed a female predominance (5/8; 62.5%). Overall, CNS GCTs in the general population most commonly occur in the pineal or suprasellar region. Interestingly, the most common site of tumor involvement in our patients was the basal ganglia (13/41; 32%). GCTs arising in the basal ganglia or thalamus are relatively rare, representing only 5%–10% of all primary intracranial GCTs.
Comparable to prior studies, patients in our cohort displayed symptoms for an average of 6.9 months prior to diagnosis. In a retrospective review of 30 patients with CNS GCTs, Crawford et al. reported a mean symptom duration of 8.4 months; symptoms, including movement disorders, enuresis, anorexia, and psychiatric complaints, led to delayed diagnosis (>6 months) in nine patients, whereas headache, nausea, vomiting, and visual changes led to earlier diagnosis. Similarly, patients in our cohort with symptoms >6 months had movement disorders (n = 3) or polyuria/polydipsia (n = 3) on presentation.

The Brain Tumor Registry of Japan reported a 5-year OS of 97% for patients with pure germinomas (n = 200) from 2001 to 2004; within their database, germinomas made up 64% of all CNS GCTs. In our study, germinomas accounted for 39% of all tumors and had a poor 3-year OS of 62%. Localized germinomas have historically been managed with WBRT/WVI followed by primary tumor boost, with CSI being reserved for disseminated germinomas. More recently, chemotherapy has been incorporated to reduce the late adverse effects caused by RT. In an analysis of the SIOP-CNS-GCT-II trial, Calaminus et al. showed that following CR to induction chemotherapy, patients with localized germinomas (n = 58) who received 24 Gy WVI without a tumor boost had a 4-year event-free survival of 98%. Furthermore, Bartels et al. demonstrated that 18 Gy WVI with 12 Gy tumor boost was associated with an excellent 3-year progression-free survival rate of 94.5%. In our cohort, most germinoma patients received RT or combined chemotherapy/RT.

In contrast to germinomas, NGGCTs are less common and associated with worse outcomes. In an analysis of the European SIOP-CNS-GCT-96 trial by Calaminus et al., 5-year OS for patients with localized NGGCTs (n = 116) was 82%. More recent trials have shown better outcomes. In a phase II trial for patients with newly diagnosed NGGCTs, Goldman et al. demonstrated a 5-year OS of 93% when neoadjuvant chemotherapy was followed by 36 Gy CSI with 54 Gy tumor-bed boost. In comparison, Fangusaro et al. showed that reduced RT (30.6 Gy WVI and 54 Gy tumor-bed boost) resulted in a similar OS of 92.4% at 3 years, though it is important to note that all patients who had treatment failure, had it in the spine. In our cohort, 3-year OS for NGGCTs was 79%.

The mainstay of treatment for intracranial mature teratomas has historically been surgical resection alone, as mature teratomas tend to be resistant to chemotherapy and RT. Since approximately 2006 and onward, immature teratomas have been managed according to NGGCT regimens, utilizing adjuvant chemotherapy ± RT followed by second-look surgery for residual tumor. The use of palbociclib for residual or growing teratomas has also been reported, though larger clinical trials are lacking. In a review of 31 patients treated for intracranial teratomas (18 mature, 13 immature) between 1979 and 2007, Lee et al. reported a 5-year OS of 74%; of these patients, 19 received perioperative chemoradiotherapy. Three-year OS for teratomas (five immature, one mature, two unspecified) in the present study was worse at 53%. Notably, all three patients who died were reported between 1975 and 1985, during which they were treated with biopsy only without any adjuvant therapy. The remaining five patients underwent GTR, with three receiving adjuvant chemotherapy.

The SIOP-96 trial reported grade 3–4 toxicities in 27/83 patients (33%) receiving combined chemotherapy/RT and 26/154 patients (17%) receiving RT only; there were no treatment-related deaths. In contrast, while 16/41 patients (39%) in the present study experienced grade 3–4 toxicities, 50% died from their toxicity (n = 8). These toxicities likely drove the poor survival rates seen in our germinoma (3-year OS: 62%) and NGGCT patients (3-year OS: 79%). While five of 16 germinoma patients (31%) died from treatment-related toxicity, just one died from tumor progression; of the NGGCT patients,
three of 16 (19%) died from treatment-related toxicity and none died from tumor progression. Trisomy-21 is associated with functional deficiencies in B-cell, T-cell, and phagocytic cell systems, resulting in an increased risk of developing and succumbing to various infectious diseases.\(^5\,7\) In an analysis of the AML-BGM-93 trial for AML, Lehrnbecher et al. found that patients with DS had significantly higher rates of infection-associated fatal complications (5/28; 17.9%) than children without DS (15/276; 5.4%).\(^5\) Notably, infection-related mortality significantly decreased in the subsequent AML-BFM 2004 trial (3/61; 4.9%), in which a reduced-intensity chemotherapy regimen was utilized.\(^7\)

Craniofacial abnormalities, increased secretions, and hypotonia associated with DS contribute to higher rates of upper-airway obstruction, particularly after the induction of anesthesia.\(^5\,2\) After tonsillectomy or adenoidectomy surgeries, Goldstein et al. found that children with DS more frequently required airway management or observation in the pediatric intensive care unit compared to controls (25% vs. 0%\(^5\)). Finally, patients with DS are at a particular risk of developing moyamoya due to cranial RT, potentially because several proteins encoded on chromosome 21, including superoxide dismutase 1, interferon gamma receptor, and cystathionine beta-synthase, affect arterial physiology as well as DNA repair.\(^6\) Given that the majority of patients in the present study died from treatment-related toxicity rather than disease progression, a reduced-intensity treatment regimen may be recommended for this population.

Our study has multiple limitations: despite being the largest cohort of patients with DS and CNS GCTs, the small number of patients limits our conclusions regarding treatment approach. Moreover, our reliance on multiple institutions limits the consistency of pathology or radiology reports, as well as tumor marker levels. The inconsistency of data reporting by previously published studies also limits the thoroughness of our retrospective cohort.

5 | CONCLUSIONS

Patients with DS treated for CNS GCTs are at an increased risk of treatment-related death, particularly from treatment-related infection. Based on our experience, we suggest that a different therapeutic approach may be considered for this patient population in which treatment intensity is reduced. To evaluate the long-term effects of RT and chemotherapy in these patients, longer follow-up is needed. An expanded multi-institutional analysis is warranted, as well as subgroup-specific analysis for DS patients within prospective clinical trials of CNS GCTs.

CONFLICT OF INTEREST

The authors do not have any conflicts of interest to disclose. No funding was used to support this work. The authors have no financial interests to disclose.

AUTHOR CONTRIBUTIONS

All authors contributed to the study conception and design. Material preparation, data collection, and data analysis were performed by Micah K. Harris and Mohamed S. Abdelbaki. The first draft of the manuscript was written by Micah K. Harris, and all authors commented on previous versions of the manuscript. All authors read and approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Micah K. Harris https://orcid.org/0000-0001-9919-5896
John R. Crawford https://orcid.org/0000-0002-4100-7001
Joseph R. Stanek https://orcid.org/0000-0003-1630-2102
Kevin X. Liu https://orcid.org/0000-0003-2071-5137
Mohamed S. Abdelbaki https://orcid.org/0000-0002-8262-7469

REFERENCES

1. Echevarría ME, Fangusaro J, Goldman S. Pediatric central nervous system germ cell tumors: a review. Oncologist. 2008;13(6):690-699.
2. Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy – state of the art review. Pediatr Blood Cancer. 2005;44(1):13-20.
3. Satgé D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. A tumor profile in Down syndrome. Am J Med Genet. 1998;78(3):207-216.
4. Sadakata E, Yoshida K, Baba S, Fuku K, Matsuo T. A case of basal ganglia germ cell tumor associated with Down’s syndrome. In: Nervous System in Children; 2021. https://www.jstage.jst.go.jp/article/jspn/46/3/46_243/_article/-char/ja/
5. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klinegebiel T, Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18(1):72-77.
6. Ullrich NJ, Robertson R, Kinnamon DD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007;68(12):932-938.
7. Hassler A, Bochennek K, Gilfert J, et al. Infectious complications in children with acute myeloid leukemia and Down syndrome: analysis of the prospective multicenter trial AML-BFM 2004. Pediatr Blood Cancer. 2016;63(6):1070-1074.
8. Maeda Y, Yoshikawa K, Kajiwara K, et al. Intracranial yolk sac tumor in a patient with Down syndrome. J Neurosurg Pediatr. 2011;7(6):604-608.
9. Komiya K, Iwamoto H, Misugi K. A case of cerebellar tumor associated with Down's syndrome. Congenit Anom (Kyoto). 1975;15:212-213.
10. Nakato H, Kuwabara S, Maesako N, et al. A case of Down’s syndrome complicated by teratoma of the third ventricle of the brain. No to Shinkei. 1982;34(2):145-150.
11. Yamasaki S, Hamasaki Y. An infant case of brain tumor associated with Down’s syndrome (in Japanese). In. Vol 54. 1985. https://scholar.google.com/scholar?hl=en&as_sdt=0%26q=A+infant+case+of+a+brain+tumor+associated+with+Down%E2%80%99s+syndrome&btnG=, https://www.karger.com/Article/Abstract/28721, https://europepmc.org/article/med/8986161
12. Fujita T, Yamada K, Saitoh H, Itosh S, Nakai O. Intracranial germinoma and Down's syndrome-case report. Neurol Med Chir (Tokyo). 1992;32(3):163-165.

13. Oshtita N, Yamashita K, Gotou K, Nagata I, Ueda H, Mitani T. [A case of endodermal sinus tumor in the basal ganglia associated with Down's syndrome]. No Shinkou Geka. 1993;21(4):345-349.

14. Wada H, Kubo M, Wada T, et al. [A case report of a 6-year-old boy with intracranial yolk sac tumor treated by VAB-6 regimen]. No Shinkou Geka. 1995;23(1):65-68.

15. Nakashima T, Nishimura Y, Sakai N, Yamada H, Harada A. Germinoma in cerebral hemisphere associated with Down syndrome. Childs Nerv Syst. 1997;13(10):563-566.

16. Hokezu Y, Okada A, Kanehisa Y, Nagamatsu K, Matsuura M. Down syndrome associated with radiosensitive brain tumor. Shenkei Naika. 1987;26(8):3.

17. Tanabe M, Mizushima M, Anno Y, et al. Intracranial germinoma with Down's syndrome: a case report and review of the literature. Surg Neurol. 1997;47(1):28-31.

18. Matsumura N, Kurimoto M, Endo S, Fukuda O, Takaku A. Intracranial germinoma associated with Down's syndrome. Report of 2 cases. Pediatr Neurosurg. 1998;29(4):199-202.

19. Chik K, Li C, Shing MM, Leung T, Yuen PM. Intracranial germ cell tumors in children with and without Down syndrome. J Pediatr Hematol Oncol. 1999;21(2):149-151.

20. Tan HW, Ty A, Goh SG, Wong MC, Hong A, Chuah KL. Yolk sac tumor of the bilateral basal ganglia in a female patient. Childs Nerv Syst. 1999;15(8):457-460.

21. Satoh S, Goto H, Izaki K, Sakuma H, Watanabe K. Intracranial germinoma associated with Down syndrome: case report and review of literature. No Shinkei Geka. 2012;40(2):137-143.

22. Sugimoto K, Ideguchi M, Sadahiro H, et al. Yolk sac tumor of the bilateral basal ganglia in a patient with Down syndrome. Brain Tumor Pathol. 2013;30(4):247-252.

23. Bakhitl X, Yanezawa H, Bohara M, et al. Posterior fossa immature teratoma in an infant with trisomy 21: a case report and review of the literature. Surg Neurol Int. 2012;3:100.

24. Robson CD, Price DL, Barnes PD, Taylor GA. Radiologic-pathologic conference of Children's Hospital Boston: pineal region mass in a neonate. Pediatr Radiol. 1997;27(10):829-831.

25. Hashimoto T, Sasagawa I, Ishigooka M, et al. Down's syndrome associated with intracranial germinoma and testicular embryonal carcinoma. Urol Int. 1995;55(2):120-122.

26. Nodomi S, Umeda K, Ueno H, et al. Efficacy of ifosfamide-cisplatin-etoposide (ICE) chemotherapy for a CNS germinoma in a child with Down syndrome. J Pediatr Hematol Oncol. 2017;39(1):e39-e42.

27. Endo S, Kobayashi H, Terasaka S, et al. Primary intracranial yolk sac tumor in the posterior fossa: case report of a child with Down syndrome. Clin Neurol Neurosurg. 2013;115(6):811-813.

28. Abu Arja MH, Conley SE, Salceda V, Al-Sufiani F, Boué DR, Finlay JL. Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome. Childs Nerv Syst. 2018;34(4):777-780.

29. Miyake Y, Adachi JI, Suzuki T, Mishima K, Sasaki A, Nishikawa R. Craniospinal germinomas in patients with down syndrome successfully treated with standard-dose chemotherapy and craniospinal irradiation: case report and literature review. World Neurosurg. 2017;108:995.e999-995.e915.

30. Tempaku A. Basal ganglia germinoma associated with down syndrome in a female patient. BAOU Neurou. 2018;4:50.

31. Takada A, Li N, Hirayama M, et al. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor. J Neurosurg Pediatr. 2018;23(3):317-324.

32. Dagri J, Torkildson J, Cheng J, et al. GC-08 central nervous system (CNS) germ cell tumors (GCT) and DOWN syndrome: treatment strategies and morbidity. Neuro-oncology. 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483347/

33. Kaatsch P, Rickert CH, Kühl J, Schür J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer. 2001;92(12):3155-3164.

34. Keene D, Johnston D, Strother D, et al. Epidemiological survey of central nervous system germ cell tumors in Canadian children. J Neurooncol. 2007;82(3):289-295.

35. Ostrom QT, De Blank PM, Kruchko C, et al. Alex's Lemonade Stand Foundation childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2015;16(1):x-x.

36. Zhou D, Zhang Y, Liu H, Luo S, Luo L, Dai K. Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005. Pediatr Neurosurg. 2008;44(2):97-103.

37. Shibui S. Report of brain tumor registry of Japan (2001–2004). Neurol Med Chir (Tokyo). 2014;54(suppl. 1). https://www.jstage.jst.go.jp/article/nmc/54/Supplement/54_sup.2014-0000/article/-char/ja/

38. Poynter JN, Fonstad R, Tolor J, Spector LG, Ross JA. Incidence of intracranial germ cell tumors by race in the United States, 1992–2010. J Neurooncol. 2014;120(2):381-388.

39. Kakkar A, Biswas A, Kalyani N, et al. Intracranial germ cell tumors: a multi-institutional experience from three tertiary care centers in India. Childs Nerv Syst. 2016;32(11):2173-2180.

40. Sano K. Pathogenesis of intracranial germ cell tumors reconsidered. J Neurosurg. 1999;90(2):258-264.

41. Wang M, Zhou P, Zhang S, et al. Clinical features, radiologic findings, and treatment of pediatric germ cell tumors involving the basal ganglia and thalamus: a retrospective series of 15 cases at a single center. Childs Nerv Syst. 2018;34(3):423-430.

42. Crawford JR, Santi MR, Vezina G, et al. CNS germ cell tumor (CNS-GCT) of childhood: presentation and delayed diagnosis. Neurology. 2007;68(20):1668-1673.

43. Sethi RV, Marino R, Niemierko A, Tarbell NJ, Yock TI, MacDonald SM. Delayed diagnosis in children with intracranial germ cell tumors. J Pediatr. 2013;163(5):1448-1453.

44. Kyritsis AP. Management of primary intracranial germ cell tumors. J Neurooncol. 2010;96(2):143-149.

45. Bartels U, Onar-Thomas A, Patel SK, et al. Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. Neuro Oncol. 2021:noab270.https://doi.org/10.1093/neuonc/noab270

46. Calaminus G, BISON B, Faure-Conter C, et al. GCT-76. 24Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in cr after initial chemotherapy – early results of the SIOP CNS GCT II study. Neuro-oncology. 2020;22(Suppl 3):iii343-iii344.

47. Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol. 2017;19(12):1661-1672.

48. Goldman S, Bouffet E, Fisher PG, et al. Phase II trial assessing the ability of naduvantr chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a Children's Oncology Group study. J Clin Oncol. 2015;33(22):2464-2471.

49. Lee YH, Park EK, Park YS, Shin KW, Choi JU, Kim DS. Treatment and outcomes of primary intracranial teratoma. Childs Nerv Syst. 2009;25(12):1581-1587.

50. Schultz KA, Petronio J, Patterson R, Vaughn DJ. PD0332991 (palbociclib) for treatment of pediatric intracranial growing teratoma syndrome. Pediatr Blood Cancer. 2015;62(6):1072-1074.
trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol. 2013;15(6):788-796.

52. Goldstein NA, Armfield DR, Kingsley LA, Borland LM, Allen GC, Post JC. Postoperative complications after tonsillectomy and adenoidectomy in children with Down syndrome. Arch Otolaryngol Head Neck Surg. 1998;124(2):171-176.

How to cite this article: Harris MK, Graham RT, Cappellano AM, et al. Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome. Pediatr Blood Cancer. 2022;69:e29830. https://doi.org/10.1002/pbc.29830